Fisetin vs Quercetin: Which Senolytic Should You Take? (2026)

Senescent cells (damaged cells that stop dividing but refuse to die, instead secreting inflammatory signals that damage surrounding healthy tissue – often called "zombie cells") are one of the most actionable targets in aging biology. They accumulate with age, drive chronic inflammation, degrade tissue function, and contribute to virtually every age-related disease.

Senolytics (compounds that selectively destroy senescent cells while leaving healthy cells intact) represent one of the most exciting therapeutic categories in longevity science. And two natural compounds dominate the conversation: fisetin and quercetin.

Both are flavonoids (plant-derived polyphenols with antioxidant and anti-inflammatory properties). Both clear senescent cells. But they do so through different mechanisms, with different potencies, different bioavailability profiles, and different bodies of evidence.

This article provides the head-to-head comparison – mechanism, efficacy, bioavailability, dosing protocols, and what the clinical trial data shows for each.

TL;DR

• Fisetin was ranked the #1 senolytic by Mayo Clinic screening (Yousefzadeh et al. 2018) – more potent than quercetin for senescent cell clearance
• Quercetin is the most studied senolytic when combined with dasatinib (D+Q protocol) – the only senolytic combination with published human trial data (Hickson et al. 2019)
• Fisetin targets BCL-2/BCL-XL anti-apoptotic proteins; quercetin targets PI3K/AKT and HIF-1α pathways
• Bioavailability is poor for both in standard form – Quercefit phytosome achieves 20x absorption; microencapsulated fisetin achieves 26.9x
• David Sinclair takes fisetin 500mg daily; the D+Q protocol uses quercetin 1,000mg in intermittent pulses
• The AFFIRM-LITE trial (fisetin) will be pivotal – results pending as of March 2026

What Makes a Compound Senolytic?

Before comparing fisetin and quercetin, it helps to understand what senolytic compounds actually do.

Senescent cells resist apoptosis (programmed cell death – the orderly process by which damaged or unnecessary cells are dismantled and recycled). They do this by upregulating anti-apoptotic pathways – essentially turning on survival signals that prevent normal cell death.

The key survival pathways senescent cells exploit include:

• BCL-2/BCL-XL family – anti-apoptotic proteins (proteins that block the cellular self-destruct mechanism) that sit on the mitochondrial membrane and prevent cytochrome c release, the trigger for apoptosis
• PI3K/AKT pathway – a growth and survival signaling cascade that promotes cell survival by inhibiting pro-apoptotic proteins
• p53/p21 axis – while p53 initially triggers senescence, some senescent cells modify the p53 pathway to become resistant to subsequent apoptotic signals
• HIF-1α – hypoxia-inducible factor that promotes survival under stress conditions
• SCAP/SCAPs (senescent cell anti-apoptotic pathways) – the collective term for the network of survival signals that keep senescent cells alive

A senolytic compound disrupts one or more of these survival pathways, tipping senescent cells from survival into apoptosis – while leaving healthy cells (which do not depend on these upregulated pathways) unaffected.

For the broader context on senescent cells and why they matter, see Senescent Cells Explained: The Zombie Cells Accelerating Your Aging. For the distinction between senolytics and senomorphics (compounds that suppress senescent cell behavior without killing them), see Senomorphics vs Senolytics: Two Approaches to Zombie Cells.

Key Takeaway: Senolytic compounds work by disabling the survival pathways that keep senescent cells alive. Different senolytics target different survival pathways – which is why fisetin and quercetin, despite both being flavonoid senolytics, have different potencies and cellular targets.

Fisetin: The Mayo Clinic's Top-Ranked Senolytic

Discovery and Ranking

Fisetin's senolytic credentials were established by a landmark 2018 study from Mayo Clinic. Yousefzadeh et al. screened 10 flavonoids for senolytic activity in human umbilical vein endothelial cells (HUVECs) and human adipose tissue (fat cells). The results, published in EBioMedicine:

Fisetin ranked #1 among all compounds tested, demonstrating the most potent and consistent senolytic activity across cell types.

When administered to aged mice (equivalent to ~75 human years), fisetin:

• Reduced senescent cell markers by approximately 50% across multiple tissues
• Extended median remaining lifespan by approximately 10%
• Reduced age-related pathology in kidneys, liver, and adipose tissue
• Decreased SASP (senescence-associated secretory phenotype – the cocktail of inflammatory molecules, growth factors, and matrix-degrading enzymes that senescent cells release, damaging surrounding tissue) markers

Mechanism of Action

Fisetin's senolytic activity is primarily mediated through:

1. BCL-2/BCL-XL inhibition: Fisetin directly binds to and inhibits BCL-2 and BCL-XL proteins on the mitochondrial membrane. By blocking these anti-apoptotic proteins, fisetin allows cytochrome c to be released into the cytoplasm, triggering the caspase cascade (the series of enzyme-driven steps that execute programmed cell death) that kills the senescent cell.
2. PI3K/AKT pathway suppression: Fisetin inhibits the PI3K/AKT survival signaling pathway, removing a second layer of protection that senescent cells use to resist apoptosis.
3. NF-κB suppression: Fisetin reduces NF-κB (nuclear factor kappa-B – a master inflammatory signaling molecule) activity, which both suppresses the SASP and reduces senescent cell survival signaling.
4. Sirtuin activation: Fisetin activates SIRT1 (similar to resveratrol, though less potently), which has indirect pro-apoptotic effects on senescent cells through p53 deacetylation.

The ITP Controversy

The NIA Interventions Testing Program (ITP) – one of the most respected aging research programs, testing compounds across multiple independent sites – tested fisetin for lifespan extension in mice. The result: fisetin did not significantly extend lifespan or improve healthspan measures in the ITP protocol.

This contradicts the Yousefzadeh et al. 2018 findings. Several possible explanations:

• Dosing protocol differences: The ITP used continuous dietary administration. Yousefzadeh used intermittent high-dose treatment. Senolytic dosing may require pulse protocols rather than continuous exposure.
• Bioavailability issues: Fisetin has extremely poor oral bioavailability in standard form (~10% absorption). The ITP protocol may not have achieved sufficient tissue concentrations.
• Mouse strain differences: The ITP uses genetically heterogeneous mice; Yousefzadeh used C57BL/6. Genetic background may influence response.

Dr. Brad Stanfield – a physician and longevity researcher – highlighted the ITP failure in a 2022 video, announcing he stopped taking fisetin and quercetin based on the lack of robust lifespan data. This is a legitimate scientific position, though other longevity researchers (including David Sinclair, who takes fisetin 500mg daily) disagree, noting that the ITP protocol may not have used an optimal dosing strategy.

AFFIRM-LITE Trial

The Fisetin to Alleviate Frailty, Inflammation, and Related Measures in Older Adults (AFFIRM-LITE) trial is the first large-scale human RCT evaluating fisetin as a senolytic. Conducted by the Mayo Clinic's James Kirkland – the pioneer of senolytic research – the trial tests intermittent high-dose fisetin in older adults.

Results are not yet published as of March 2026. This trial will likely be decisive for fisetin's clinical future.

Key Takeaway: Fisetin ranked #1 in Mayo Clinic's senolytic screening, demonstrating potent senescent cell clearance and lifespan extension in mice. However, the NIA's ITP failed to replicate lifespan extension – possibly due to dosing protocol and bioavailability limitations. The AFFIRM-LITE trial will be pivotal for determining fisetin's clinical value.

Quercetin: The Most Studied Senolytic in Humans

The D+Q Protocol

Quercetin's senolytic story is inseparable from dasatinib. The dasatinib + quercetin (D+Q) combination – developed by James Kirkland's Mayo Clinic lab – is the most extensively studied senolytic regimen in humans.

Dasatinib is a tyrosine kinase inhibitor (a cancer drug that blocks specific enzymes promoting cell growth) originally developed for leukemia treatment. Quercetin is a flavonoid found in onions, apples, capers, and berries.

Why the combination? Kirkland's team found that senescent cells in different tissues rely on different survival pathways. Dasatinib is more effective against senescent fat cell progenitors and senescent bone marrow stem cells. Quercetin is more effective against senescent endothelial cells (the cells lining blood vessels). Together, they cover a broader range of senescent cell types.

Hickson et al., 2019 – The First Human Senolytic Trial

This landmark study from Mayo Clinic (EBioMedicine, n=14) was the first published human trial of any senolytic:

• Population: 9 patients with diabetic kidney disease (a condition with high senescent cell burden)
• Protocol: Dasatinib 100mg + quercetin 1,000mg, administered for 3 consecutive days
• Key findings: Significant reduction in senescent cell markers (p16INK4a – a protein that accumulates in senescent cells and is used as a biomarker for cellular senescence – positive cells, p21-positive cells) in adipose tissue biopsies. SASP factors (IL-6, MMP-9, MMP-12) were reduced. The effects persisted for at least 11 days after the 3-day treatment – consistent with senolytic clearance rather than temporary suppression.

Subsequent D+Q Human Trials

Several additional human studies have been published:

1. Justice et al., 2019 (EBioMedicine, n=14): D+Q improved physical function (6-minute walk distance, gait speed, chair-stand time) in patients with idiopathic pulmonary fibrosis (IPF – a progressive lung disease with high senescent cell burden).
2. Hickson et al., 2023 follow-up: Extended observation confirmed D+Q's senescent cell reduction was durable across multiple treatment cycles.
3. Gonzales et al., 2024 (Aging, n=19): D+Q in older adults measuring DNA methylation clocks. Showed significant epigenetic age acceleration at 3 and 6 months by first-generation clocks, but the addition of fisetin to the protocol appeared to mitigate this effect.

Quercetin's Mechanism of Action

Quercetin targets different survival pathways than fisetin:

1. PI3K/AKT pathway: Quercetin is a potent inhibitor of PI3K signaling, blocking the survival cascade at its upstream initiation point.
2. HIF-1α inhibition: Quercetin suppresses hypoxia-inducible factor 1-alpha, a transcription factor that senescent cells use to survive under metabolic stress.
3. BCL-2 family (weaker): Quercetin has modest BCL-2 inhibitory activity – less potent than fisetin at this specific target.
4. Broad anti-inflammatory effects: Quercetin inhibits NF-κB, COX-2 (cyclooxygenase-2, an enzyme that produces inflammatory prostaglandins), and multiple pro-inflammatory cytokines (signaling proteins that promote inflammation). This gives quercetin broader anti-inflammatory utility beyond its senolytic activity.

Key Takeaway: Quercetin, combined with dasatinib, is the only senolytic with published human trial data showing clearance of senescent cells in vivo. The D+Q protocol achieved significant reduction in senescent cell markers and improved physical function in disease populations. Quercetin alone is a weaker senolytic than fisetin, but in combination with dasatinib, it covers a broader range of senescent cell types.

Head-to-Head Comparison

Bioavailability: The Critical Variable

Both fisetin and quercetin suffer from poor oral bioavailability in their standard forms. This is arguably the most important practical consideration – a compound cannot clear senescent cells if it cannot reach them in sufficient concentrations.

Fisetin Bioavailability

Standard fisetin has approximately 10% oral bioavailability due to:

• Poor aqueous solubility (fisetin is a lipophilic molecule)
• Extensive first-pass metabolism (the liver breaks down much of the dose before it reaches systemic circulation)
• Rapid conjugation (attachment of glucuronide and sulfate groups that deactivate the molecule)

Microencapsulation dramatically improves fisetin bioavailability. A study by Kadari et al. (2018, Drug Delivery) found that lipid nanoparticle formulation increased fisetin's AUC (area under the curve – the total drug exposure over time, measuring both how much compound is absorbed and how long it circulates) by 26.9-fold compared to standard fisetin.

For practical purposes, this means 100mg of microencapsulated fisetin may deliver more active compound to tissues than 500mg of standard fisetin. See Bioavailability: Why the Form of Your Supplement Matters More Than the Dose for the complete science of supplement absorption.

Quercetin Bioavailability

Standard quercetin has approximately 17% oral bioavailability – slightly better than fisetin, but still poor.

Quercefit (quercetin phytosome) is a patented formulation where quercetin is complexed with sunflower phospholipids. This phytosome technology (a delivery method where the active compound is embedded in a phospholipid complex, improving absorption through the intestinal membrane) achieves approximately 20-fold greater absorption than standard quercetin, as demonstrated by Riva et al. (2019, European Review for Medical and Pharmacological Sciences, n=50).

Quercefit at 500mg delivers quercetin equivalent to approximately 10,000mg (10g) of standard quercetin – a dose that would be impractical to achieve with conventional supplements.

What This Means for Dosing

If you are choosing between fisetin and quercetin for senolytic purposes, the formulation matters as much as the compound:

Key Takeaway: Bioavailability is the bottleneck for both compounds. Standard forms of fisetin and quercetin require high doses to achieve meaningful tissue concentrations. Microencapsulated fisetin (26.9x) and Quercefit phytosome quercetin (20x) dramatically improve absorption, making lower doses clinically relevant. When comparing products, the formulation technology matters more than the raw dose listed on the label.

Dosing Protocols: Daily vs Pulse

One of the most important questions in senolytic supplementation is whether to dose daily or intermittently.

The Case for Pulse Dosing

The D+Q protocol uses intermittent pulse dosing: high doses for 2–3 consecutive days, repeated monthly or quarterly. The rationale:

1. Senolytics don't need to be present continuously. Once a senescent cell is killed, it is gone. The goal is periodic clearance, not continuous presence.
2. Senescent cells accumulate slowly. New senescent cells form gradually over weeks to months. A monthly pulse clears the accumulated burden.
3. Reduced side effect exposure. Limiting drug exposure to 2–3 days per month minimizes potential adverse effects.
4. Kirkland's team specifically designed the D+Q protocol this way based on the biology of senescent cell turnover.

Typical pulse protocol:

• Fisetin: 1,000–2,000mg/day for 2 consecutive days, once monthly
• D+Q: Dasatinib 100mg + Quercetin 1,000mg for 3 consecutive days, once monthly

The Case for Daily Dosing

David Sinclair takes fisetin 500mg daily. The rationale:

1. Continuous low-level senolytic pressure may prevent senescent cells from accumulating in the first place
2. Fisetin has additional benefits beyond senolysis – antioxidant, anti-inflammatory, neuroprotective effects that benefit from daily presence
3. Lower daily doses may have different mechanisms than high pulse doses – more senomorphic (suppressing SASP) than senolytic at lower concentrations

Which Protocol Is Better?

No head-to-head trial has compared daily vs pulse dosing in humans. The Gonzales et al. 2024 study provides some insight: participants receiving D+Q in a pulse protocol showed increases in epigenetic age acceleration (measured by first-generation clocks), while the addition of fisetin appeared to mitigate this effect. The implications are complex and require further study.

The biologically coherent position: pulse dosing for acute senolytic clearance, daily low-dose for ongoing SASP suppression. Some practitioners combine both approaches – a monthly high-dose pulse with daily low-dose maintenance.

Key Takeaway: Pulse dosing (high dose for 2–3 days, monthly) is the protocol used in human senolytic trials and is based on the biology of senescent cell turnover. Daily low-dose may offer continuous anti-inflammatory benefits. No trial has compared the two approaches. The D+Q protocol is specifically designed as a pulse regimen.

When Might You Choose One Over the Other?

Choose Fisetin If:

• You want the most potent standalone senolytic (based on Mayo Clinic screening)
• You prefer a food-derived compound without prescription drug components
• You can source microencapsulated fisetin for enhanced bioavailability
• You follow David Sinclair's approach of daily low-dose supplementation
• You want dual senolytic and neuroprotective benefits (fisetin crosses the blood-brain barrier)

Choose Quercetin If:

• You want the senolytic with the most human trial data (D+Q protocol)
• You value the broader anti-inflammatory profile (NF-κB, COX-2, multiple cytokines)
• You can source Quercefit phytosome for enhanced bioavailability
• You want a compound with additional benefits for allergies, immune regulation, and gut health
• You prefer the pulse dosing approach validated in clinical trials

Consider Both If:

• They target partially different survival pathways – combining may cover more senescent cell types
• The Gonzales et al. 2024 study suggested adding fisetin to D+Q may mitigate some negative epigenetic effects
• Some longevity practitioners alternate monthly: fisetin one month, D+Q the next

Safety Considerations

Fisetin Safety

Fisetin has no reported serious adverse events in human use. Common considerations:

• GI effects: Mild nausea or stomach discomfort at high doses (>1g), especially on an empty stomach
• Blood sugar: Fisetin may modestly lower blood glucose – monitor if on diabetes medications
• Anticoagulant interaction: Fisetin has mild antiplatelet effects – use caution if on blood thinners
• Pregnancy/breastfeeding: No safety data – avoid

Quercetin Safety

Quercetin has a longer safety history given its widespread use as a supplement:

• GI effects: Mild at standard doses; diarrhea possible above 1g
• Drug interactions: Quercetin inhibits CYP3A4 and CYP2C9 enzymes (liver enzymes that metabolize many medications), potentially increasing blood levels of certain drugs including cyclosporine, felodipine, and some statins
• Thyroid: High-dose quercetin may interfere with thyroid hormone synthesis – relevant for those with hypothyroidism
• Kidney concerns: Very high doses (>2g daily) have raised theoretical concerns about renal effects; standard supplemental doses show no kidney issues

Safety Warning: The D+Q protocol includes dasatinib, a prescription chemotherapy drug with significant side effects (edema, GI bleeding, pleural effusion, myelosuppression). Do NOT self-prescribe dasatinib. The D+Q protocol should only be administered under physician supervision, ideally by a clinician experienced with senolytic protocols.

Safety Note: High-dose senolytics should be used with caution. Fisetin and quercetin can interact with blood thinners and chemotherapy agents. Pulse dosing protocols (2 consecutive days/month) should not be exceeded without medical supervision.

Food Sources: Can You Get Enough From Diet?

Both fisetin and quercetin occur naturally in foods, but the concentrations are far below therapeutic senolytic doses:

Fisetin in Foods

Strawberries are by far the richest food source, but even eating a kilogram of strawberries daily would deliver less than 200mg of fisetin – and only if it all survived digestion and absorption, which it does not.

Quercetin in Foods

Capers are exceptionally rich in quercetin, but consuming nearly half a kilogram of capers daily is neither practical nor enjoyable. Supplementation is the only realistic way to achieve senolytic-relevant doses of either compound.

This is an important distinction from compounds like vitamin C or omega-3s, where dietary intake can meaningfully contribute to therapeutic levels. For senolytics, supplementation is not a convenience – it is a necessity.

The Inflammaging Connection

Both fisetin and quercetin contribute to reducing inflammaging (chronic, low-grade, sterile inflammation that increases with age and drives most age-related diseases). Senescent cells are a primary source of inflammaging through their SASP secretions.

By clearing senescent cells (senolytic effect) and suppressing SASP factors (senomorphic effect), both compounds address inflammaging from its source rather than just managing downstream symptoms. See Inflammaging: How Chronic Inflammation Accelerates Aging for the complete mechanism.

Quercetin's broader anti-inflammatory profile – inhibiting NF-κB, COX-2, lipoxygenase, and multiple pro-inflammatory cytokines – gives it an edge for general inflammation management. Fisetin's advantage is more targeted: potent senolytic clearance with SIRT1 activation for additional epigenetic benefits. For detailed evidence scores on both fisetin and quercetin, along with 25+ other longevity compounds, visit the Compound Index.

Frequently Asked Questions

Related Reading

• Fisetin: The Senolytic Compound That Clears Zombie Cells
• Senescent Cells Explained: The Zombie Cells Accelerating Your Aging
• Senomorphics vs Senolytics: Two Approaches to Zombie Cells
• Bioavailability: Why the Form of Your Supplement Matters More Than the Dose
• Inflammaging: How Chronic Inflammation Accelerates Aging
• David Sinclair's Supplement Stack (2026)

References:

• Yousefzadeh MJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18–28.
• Hickson LJ, et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin. EBioMedicine. 2019;47:446–456. n=9.
• Justice JN, et al. Senolytics in idiopathic pulmonary fibrosis. EBioMedicine. 2019;40:554–563. n=14.
• Gonzales MM, et al. Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial. Nature Medicine. 2023. n=5.
• Gonzales MM, et al. Exploring the effects of dasatinib, quercetin, and fisetin on DNA methylation clocks. Aging. 2024;16(4):3088–3106. n=19.
• Riva A, et al. Improved oral absorption of quercetin from quercetin Phytosome, a new delivery system based on food grade lecithin. Eur J Drug Metab Pharmacokinet. 2019;44(2):169–177. PMID 30328058.
• Kadari A, et al. Enhanced oral bioavailability of fisetin by lipid nanoparticle formulation. Drug Delivery. 2018.
• Park SJ, et al. Resveratrol ameliorates aging-related metabolic phenotypes. Cell. 2012;148(3):421–433. (AMPK/sirtuin pathway context)
• NIA Interventions Testing Program. Fisetin lifespan study results. Published 2022.

These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.